Bristol-Myers Squibb (NYSE:BMY) Reaches New 1-Year Low at $43.73

Shares of Bristol-Myers Squibb (NYSE:BMY - Get Free Report) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $43.73 and last traded at $43.78, with a volume of 1107105 shares traded. The stock had previously closed at $43.94.

Analysts Set New Price Targets

BMY has been the topic of a number of recent analyst reports. BMO Capital Markets lowered their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a "market perform" rating on the stock in a research report on Friday, April 26th. Societe Generale downgraded Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a research report on Monday, March 11th. William Blair restated a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Redburn Atlantic downgraded Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and lowered their price target for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. Finally, Barclays lowered their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an "equal weight" rating on the stock in a research report on Friday, April 26th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $60.00.

Bristol-Myers Squibb Stock Up 0.6 %

The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The company has a market capitalization of $89.62 billion, a P/E ratio of -14.21, a PEG ratio of 15.39 and a beta of 0.39. The company has a 50 day moving average of $50.81 and a 200-day moving average of $50.93.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to analysts' expectations of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb's quarterly revenue was up 4.7% on a year-over-year basis. During the same period last year, the firm earned $2.05 earnings per share. As a group, equities analysts anticipate that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a $0.60 dividend. The ex-dividend date is Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 5.43%. Bristol-Myers Squibb's payout ratio is presently -77.42%.

Institutional Trading of Bristol-Myers Squibb

Large investors have recently bought and sold shares of the company. OFI Invest Asset Management bought a new stake in Bristol-Myers Squibb during the 3rd quarter valued at approximately $25,000. Milestone Investment Advisors LLC purchased a new position in shares of Bristol-Myers Squibb during the third quarter valued at approximately $27,000. Northwest Financial Advisors purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $27,000. Blue Bell Private Wealth Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 61.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 200 shares during the last quarter. Finally, Accordant Advisory Group Inc purchased a new position in shares of Bristol-Myers Squibb during the first quarter valued at approximately $31,000. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.